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factor, is critical for jejunal identity. Mice with an intestine-spe-
ciﬁc GATA4 deﬁciency (GATA4iKO) are resistant to diet-induced
obesity and insulin resistance. Although they have decreased
intestinal lipid absorption, hepatic de novo lipogenesis is inhib-
ited. Here, we investigated dietary lipid-dependent and indepen-
dent effects on the development of steatosis and ﬁbrosis in
GATA4iKO mice.
Methods:GATA4iKO and control mice were fed a Western-type
diet (WTD) or a methionine and choline-deﬁcient diet (MCDD)
for 20 and 3 weeks, respectively. Functional effects of GATA4iKO
on diet-induced liver steatosis were investigated.
Results:WTD-but not MCDD-fed GATA4iKO mice showed lower
hepatic concentrations of triglycerides, free fatty acids, and thio-
barbituric acid reactive species and had reduced expression of
lipogenic as well as ﬁbrotic genes compared with controls.
Reduced nuclear sterol regulatory element-binding protein-1c
protein levels were accompanied by lower lipogenic gene expres-
sion. Oil red O and Sirius Red staining of liver sections conﬁrmed
the observed reduction in hepatic lipid accumulation and ﬁbrosis.
Immunohistochemical staining revealed an increased number of
jejunal glucagon-like peptide 1 (GLP-1) positive cells in GATA4iKO
mice. Consequently, we found enhanced phosphorylation of
hepatic AMP-activated protein kinase and acetyl-CoA carboxylase
alpha.Journal of Hepatology 20
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hepatic steatosis and ﬁbrosis via GLP-1, thereby blocking hepatic
de novo lipogenesis.
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Metabolic syndrome is a state of metabolic deregulation charac-
terized by obesity, hyperlipidemia, atherosclerosis, glucose intol-
erance, and hepatic steatosis [1]. A key mechanism contributing
to the development of metabolic syndrome is the rate of hepatic
de novo lipogenesis (DNL) [2]. Hepatic DNL contributes only 5% of
liver triglycerides (TG) under healthy circumstances but up to
30% in case of non-alcoholic fatty liver disease (NAFLD) [3]. The
derangement of DNL in murine models of high fat diet-induced
hepatic steatosis underscores the intestinal contribution in regu-
lating hepatic lipid metabolism. Western-type diet (WTD), which
is generally used to induce atherosclerosis, insulin resistance, and
metabolic syndrome in mice, also causes non-alcoholic steato-
hepatitis [4,5]. WTD contains 43% of calories in the form of carbo-
hydrates and dietary carbohydrates are known to activate hepatic
DNL via acetyl-CoA carboxylase (ACC) [6]. Methionine and cho-
line-deﬁcient diet (MCDD) is widely used as a model of hepatic
steatosis and ﬁbrosis by inhibiting the release of very low density
lipoproteins and by decreasing mitochondrial fatty acid oxidation
[7].
Ileum of the small intestine is an important endocrine organ,
which signals the dietary status to other organs including the
liver by the release of hormones such as glucagon-like peptide-
1 (GLP-1) [8,9]. A recent meta-analysis of 15 studies has investi-
gated the effect of various bariatric procedures on NAFLD. The
study has concluded that bariatric surgery ameliorates steatosis
in 92%, steatohepatitis in 81% and leads to complete resolution
in 70% of patients [10]. Ileal interposition surgery (IIS) is one of
the bariatric procedures that mitigate the metabolic syndrome
[11]. IIS in rats improves glucose tolerance and increases synthe-
sis and release of GLP-1 and peptide YY [12,13]. Kohli et al. have
recently reported that the cycling of bile acids is increased in rats
that have undergone IIS and that these mice are protected from12 vol. 57 j 1061–1068
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obesity-associated co-morbidities [14]. These studies provide evi-
dence that postsurgical changes in intestinal anatomy and func-
tion, especially earlier exposure of the ileum to nutrients
together with alterations in the secretion of enteric hormones,
contribute to improve glucose tolerance and lipid homeostasis
after IIS. However, the long-term effects this surgical procedure
may exert on hepatic lipid metabolism, steatosis, ﬁbrosis, and
inﬂammation are still unknown.
GATA4, a zinc ﬁnger domain transcription factor expressed
throughout the small intestine except the distal ileum, plays an
important role in maintaining jejuno-ileal differences in absorp-
tive enterocyte gene expression [15,16]. Using a Villin-Cre
approach, Battle et al. generated intestine-speciﬁc GATA4 knock-
out (GATA4iKO) mice and showed that 47% of ileal genes were
ectopically expressed in the jejunum of these mice [15]. This
jejuno-ileal transition resembles IIS. We have previously demon-
strated that GATA4iKO mice were resistant to diet-induced obes-
ity and insulin resistance owing to reduced intestinal lipid
absorption and increased GLP-1 release [17].
In the present study, we have investigated the effect of intes-
tinal GATA4 deﬁciency on hepatic steatosis and ﬁbrosis. Using
two dietary conditions, we provide evidence that decreased
hepatic DNL leads to protection from diet-induced NAFLD in
GATA4iKO mice.Materials and methods
Animals and diets
Generation of Gata4loxP/nullVillin-Cre knockout and Gata4loxP/+ Villin-Cre control
mice have previously been described [15]. All experiments were performed using
male mice. Mice had free access to food and water under a 12 h light/12 h dark
cycle in a temperature-controlled environment. Individually housed knockout
and control littermates were fed a normal chow diet (11.9% caloric intake from
fat, Ssniff, Soest, Germany) or switched to WTD (TD88137 mod.; Ssniff, Soest,
Germany) for 20 or MCDD (A02082002B, Research Diets, Inc. New Brunswick,
NJ) for 3 weeks. WTD contained 21% (weight/weight) crude fat and 0.15%
(weight/weight) cholesterol with  4.53 kcal/g (42% of calories from crude fat,
15% from protein, and 43% from carbohydrate). Features of metabolic syndrome
along with steatohepatitis are reported to develop after long-term WTD feeding
[4]. MCDD is reported to induce severe steatohepatitis in a relatively shorter time
period from 3 to 6 weeks [7]. Appropriate feeding regimens were chosen accord-
ingly. Animal experiments were performed in accordance with the standards
established by the Austrian Federal Ministry of Science and Research, Division
of Genetic Engineering and Animal Experiments (Vienna, Austria).
Biochemical analyses
Blood was drawn via retro-orbital puncture and plasma was isolated for analysis.
Levels of alanine aminotransferase (ALT), aspartate transaminase (AST), and lac-
tate dehydrogenase (LDH) were routinely measured in 4 mice per genotype.
Oral fat tolerance test
Blood was drawn via retro-orbital puncture before and after an oral gavage of
200 ll of corn oil at pre-established time points and plasma was isolated. Plasma
TG (n = 8/group) was estimated according to manufacturer’s protocol (DiaSys,
Holzheim, Germany).
Hepatic TG and free fatty acid (FFA) estimation
Hepatic TG and FFA concentrations were determined from Folch extracts using
enzymatic kits according to manufacturer’s protocols (DiaSys, Holzheim, Ger-
many; Wako Chemicals GmbH, Neuss, Germany). Brieﬂy, liver samples from
GATA4iKO and control mice fed WTD (n = 5/group), MCDD (n = 4/group) or chow1062 Journal of Hepatology 2012diet (n = 5/group) were weighed and homogenized, and lipids were extracted in
chloroform:methanol (2:1) in a volume 20 times the weight of the sample. Lipid
extracts were then solubilized in freshly prepared 0.2% Triton X-100 in chloro-
form, dried under a gentle stream of nitrogen, and resuspended in 200 ll sterile
phosphate-buffered saline.
Assay for hepatic lipid peroxidation levels
Hepatic levels of thiobarbituric acid reactive substances (TBARS) were deter-
mined using the Cayman TBARS Assay kit (Cayman Chemicals, Ann Arbor, MI).
Brieﬂy, 25 mg of liver tissue from WTD-fed control and GATA4iKO mice (n = 5/
group) was homogenized in 250 ll of radio-immunoprecipitation assay buffer
supplemented with protease inhibitors (Roche, Indianapolis, IN) and sonicated
on ice for 15 s at medium power. Supernatants were separated by centrifugation
at 3500 rpm for 10 min at 4 C. One hundred ll of each sample and standard was
mixed with 4 ml color reagent containing 100 ll of sodium dodecyl sulfate solu-
tion. Samples were boiled for 1 h, and the reaction was stopped by placing sam-
ples on ice for 10 min. Thereafter, samples were centrifuged at 3500 rpm for
10 min at 4 C. The absorbance was measured at 530 nm. Results were expressed
as lM of malondialdehyde-adduct per g liver weight.
Assay for hepatic 4-hydroxyproline levels
Hepatic levels of 4-hydroxyproline were measured as previously described [18].
Brieﬂy, liver tissues were homogenized in 2 N NaOH and autoclaved at 120 C
for 25 min for alkaline hydrolysis. The hydrolysates were cooled to RT and ﬁltered
through Whatmann ﬁlter paper No. 1 to remove particulate matter. Standard
dilutions of 4-hydroxyproline (Sigma Aldrich, GmbH, Germany), samples and
blanks in acetate-citrate buffer pH 6.5 were mixed in freshly prepared chloramine
T and allowed to react at room temperature for 25 min. Color development was
achieved by the addition of fresh Ehrlich’s aldehyde reagent and incubation at
65 C for 20 min. Absorbances were measured at 550 nm. Results were plotted
as mg collagen/g liver using the following formula:
g collagen ¼ ðg 4-hydroxyproline=mlÞ  dilution factor  conversion factorð7:5ÞHistochemistry and immunohistochemistry
For conventional light microscopy, livers of WTD-fed control and GATA4iKO
mice (n = 3/group) and MCDD-fed control and GATA4iKO mice (n = 4/group)
were ﬁxed in 4% neutral buffered formaldehyde solution for 24 h and embedded
in parafﬁn. Five lm sections were deparafﬁnized and subjected to routine hae-
matoxylin and eosin, periodic acid Schiff and Sirius Red staining. For histochem-
ical staining with Oil Red O, 7 lm cryosections were prepared and stained
according to protocol; nuclei were counter-staining with Mayer’s haematoxylin.
For the detection of GLP-1 positive cells in the jejunum of control and GATA4iKO
mice, harvested jejunum was longitudinally exposed and luminal contents were
washed in PBS. The tissue was immediately ﬁxed in 10% formaldehyde for 24 h
and embedded in parafﬁn. Five lm sections were processed for staining. Sec-
tions were deparafﬁnized and blocked in 2% pre-immune goat serum. Sections
were incubated with anti-GLP-1 antibody (1:500; Phoenix Pharmaceuticals
Inc., Burlingame, CA) overnight at 4 C, washed, incubated with biotinylated
goat anti-rabbit secondary antibody followed by signal enhancement using
the ABC reagent (Vector Laboratories Inc., Burlingame, CA). Horse radish perox-
idase was detected using the 3,30-diaminobenzidine with metal enhancer
reagent (Sigma Aldrich, St. Louis, MO). Images were acquired using an Olympus
FSX100 at indicated magniﬁcations.
RNA isolation and quantitative real-time PCR
Total RNA from tissues of mice was isolated using the TriFast reagent according
to the manufacturer’s protocol (Peqlab Biotechnologies GmbH, Erlangen, Ger-
many). Two lg of total RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Quantita-
tive real-time PCR was performed on a Roche LightCycler 480 instrument (Roche
Diagnostics, Palo Alto, CA) using the QuantiFast™ SYBR Green PCR Kit (Qiagen,
Valencia, CA). Samples were measured in triplicate for each experiment and nor-
malized to cyclophilin A mRNA expression as an internal control. Expression pro-
ﬁles and associated statistical parameters were analyzed using the public domain
program Relative Expression Software Tool – REST 2010 (http://www.gene-quan-
tiﬁcation.com/download.html) [19]. Primer sequences are available upon
request.vol. 57 j 1061–1068
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Western blotting
Livers from WTD-fed control and GATA4iKO mice were homogenized in radio-
immunoprecipitation assay buffer and whole cell lysates were prepared and
solubilized in Laemmli sample buffer. Proteins were resolved on precast Mini-
PROTEAN–TGX gels (BioRad, Hercules, CA), blotted onto nitrocellulose mem-
branes, blocked with 5% bovine serum albumin and probed with the appropriate
polyclonal primary antibody overnight. After incubation with horseradish perox-
idase-conjugated secondary antibody (Invitrogen, Carlsbad, CA), the immunore-
active proteins were detected using the enhanced chemiluminescence detection
reagent (GE Healthcare, Piscataway, NJ). Antibodies against AMP-activated pro-
tein kinase (AMPK), phosphorylated (p)AMPK(Y172), acetyl-CoA carboxylase alpha
(ACC), pACC(S79), p38 mitogen-activated protein kinase (p38), and p-p38(T180/
Y182) were purchased from Cell Signaling Technology, Danvers, MA. Antibody
against alpha smooth muscle actin (a-SMA) was purchased from Abcam,
Cambridge, MA. For detection of the nuclear form of sterol regulatory element-
binding protein 1 c (SREBP1c), 30 lg of hepatic nuclear extract prepared by using
NE-PER nuclear cytoplasmic extraction reagents (Thermo Fisher Scientiﬁc,
Pittsburgh, PA) was blotted and detected using an anti-SREBP1 antibody (Abcam,
Cambridge, MA). The antibody against LaminA/C (Santa Cruz Biotechnology, Santa
Cruz, CA) was a gift from Dr. W. Sattler (Medical University of Graz, Austria).
Relative densities compared with controls were calculated from the percent area
under the curve using Image J.C Control
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***Statistical analysis
Plasma parameters were compared using two parameter analysis of variance
(Two-way ANOVA) followed by Bonferroni post-test. Hepatic TG, FFA, hepatic
TBARS concentrations, and histochemical scorings were compared using the
non-parametric Mann–Whitney test. Statistical signiﬁcance for the oral fat toler-
ance was calculated using one way analysis of variance. Statistical analysis of
mRNA expression levels REST 2010 was used [19]. Values are mean ± SE.
⁄p <0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.001.D Control
n.s.
SREBP1c
Lamin A
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Fig. 1. Reduced hepatic triglyceride (TG) concentrations in Western-type diet
(WTD)-fed GATA4iKO mice. (A) Hepatic TG levels in Folch extracts of control and
GATA4iKO mice fed chow and WTD (n = 5/group). (B) Representative Oil Red O
stained images of liver sections from control and GATA4iKO mice fed WTD,
showing TG (red) and nuclei (blue). (C) Plasma TG concentrations from three
experiments (n = 5/group per experiment) of oral fat tolerance test expressed as
percent of time 0. (D) Nuclear protein abundance of sterol response element-
binding protein 1c (SREBP1c) and levels of lamin A/C as loading control. Values
are means ± SE. ⁄p <0.05, ⁄⁄⁄p <0.001. n.s., not speciﬁc.
Table 1. Plasma parameters of hepatic damage in WTD-fed GATA4iKO mice
compared to controls.
Control GATA4iKO 
ALT (IU/L) 149.69 ± 32.05 41.36 ± 18.03**
AST (IU/L) 139.0 ± 37.72 61.3 ± 11.72*
LDH (IU/L) 308.3 ± 48.05 181.7 ± 48.65* 
Values are means ± SE (n = 5/group). ⁄p <0.05, ⁄⁄p <0.01.Results
Reduced hepatic TG accumulation, SREBP-1c maturation, and
lipogenic gene expression in GATA4iKO mice fed WTD
When fed a chow diet, GATA4iKO mice showed identical hepatic
TG content (Fig. 1A). Twenty weeks of WTD feeding led to an
increase in hepatic TG concentrations in both genotypes.
GATA4iKO mice had a 44% reduction in hepatic TG levels com-
pared with controls (Fig. 1A). These results were conﬁrmed by
Oil Red O staining of livers from WTD-fed control and GATA4iKO
mice (Fig. 1B). Thus, the lack of intestinal GATA4 prevented diet-
induced hepatic TG accumulation. To test for liver function, we
measured serum concentrations of ALT, AST, and LDH and found
them to be markedly reduced in GATA4iKO mice compared with
controls (Table 1). WTD feeding also led to a decrease in body
weight gain in GATA4iKO mice (Supplementary Fig. 1). To inves-
tigate the underlying mechanism of reduced hepatic TG accumu-
lation, we ﬁrst determined oral fat tolerance, which was
prominently reduced in GATA4iKO mice (Fig. 1C). To compensate
for the reduced intestinal uptake, we expected a proportional
increase in hepatic DNL in GATA4iKO mice. Interestingly, hepatic
Srebp-1c mRNA expression was reduced by 71% in WTD-fed
GATA4iKO compared with control mice (Table 2). Livers from
GATA4iKO animals lacked mature SREBP1c protein (Fig. 1D).
Accordingly, hepatic mRNA expression of lipogenic targets of
SREBP-1c was markedly decreased such as CD36 antigen, glyc-
erol-3-phosphate acyltransferase 1, fatty acid synthase, acetyl-
CoA carboxylase alpha, and stearoyl-CoA desaturase 1 in
GATA4iKO compared with control mice (Table 2).Journal of Hepatology 2012Increased GLP-1 positive cells and AMPK activation in livers of
GATA4iKO mice
Next, we investigated the mechanism by which the lack of
intestinal GATA4 suppressed hepatic maturation of SREBP-1cvol. 57 j 1061–1068 1063
Table 2. mRNA fold change and p value for various genes in WTD-fed
GATA4iKO mice compared to controls.
Gene name Fold 
change
p value
Lipogenesis
Sterol regulatory element-binding protein-1c 0.290*** 0.001
CD36 antigen 0.226*** 0.001
Glycerol-3-phosphate acyltransferase 1 0.491*** 0.001
Fatty acid synthase 0.348*** 0.001
Acetyl-CoA carboxylase alpha 0.390*** 0.001
Stearoyl-CoA desaturase 1 0.487*** 0.001
Fibrosis
Collagen type I 0.267*** 0.001
Collagen type III 0.582** 0.011
Tissue inhibitor of metalloproteinases 1 0.313*** 0.001
Tissue inhibitor of metalloproteinases 2 0.847 0.595
Actin, alpha-2 0.468*** 0.001
Peroxisome proliferator-activated receptor 
gamma
7.087*** 0.001
Enteroendocrine
Glucagon like peptide-1 (Jej) 3.840*** 0.001
Glucagon like peptide-1 receptor (Liv) 0.947 0.433
Tumor necrosis factor alpha 0.411*** 0.001
Interferon gamma 0.435* 0.046
Interleukin 1β 0.598** 0.010
Interleukin 6 0.521** 0.019
Interleukin 12 0.580** 0.019
Inflammatory markers
Jej, Jejunum; Liv, Liver.
Values are means ± SE (n = 5/group). ⁄p <0.05 ⁄⁄p <0.01, ⁄⁄⁄p <0.001.
Research Articleand lipogenic gene expression. Previous reports in inducible
intestine-speciﬁc GATA4 knockout mice had shown that intestinal
posteriorization led to a shift in cell type composition [15,20]. In
agreement with these data, we observed a 1.4-fold increase in
goblet cells in GATA4iKO jejuna [20] (Fig. 2A). To test whether
intestinal posteriorization also led to an anterior increase in
GLP-1 secreting L-cells, we stained for GLP-1, revealing 1.7-fold
more GLP-1 positive cells in GATA4iKO compared with control jej-
una (Fig. 2B). In accordance, jejunal transcript levels of Glp-1were
3.8-fold upregulated in GATA4iKO mice while hepatic expression
of Glp-1 receptor was comparable in GATA4iKO and control livers
(Table 2). Since GLP-1 is known to suppress hepatic lipogenesis
via activation of AMPK [21], we determined hepatic phosphoryla-
tion of AMPK and its target ACC. As shown in Fig. 2C and D, hepa-
tic phosphorylation of both AMPK(Y172) and ACC(S79) was
increased in GATA4iKO compared with control mice. Consistent
with our ﬁnding of suppressed Acc transcript levels (Table 2),
we also found a dramatic reduction of ACC protein expression
in GATA4iKO livers (Fig. 2D).
Reduced hepatic FFA concentrations, lipid peroxidation, and ﬁbrosis
in WTD-fed GATA4iKO mice
Hepatic accumulation of peroxidated lipids leads to oxidative
damage contributing to hepatic injury [22]. We therefore1064 Journal of Hepatology 2012determined the levels of FFA and TBARS in the liver. We found
a 41% reduction in hepatic FFA concentrations (Supplementary
Fig. 2) and a 19% decrease in hepatic lipid peroxidation
(Fig. 3A) in WTD-fed GATA4iKO compared with control mice. As
a result, GATA4iKO mice had lower levels of p38 phosphorylation
(Fig. 3B).
To assess the ﬁbrotic potential of WTD in our model, we deter-
mined 4-hydroxyproline concentrations (presented as mg colla-
gen normalized to liver weight), Sirius Red staining and
localization and protein expression levels of a-SMA. WTD led to
a 2.2-fold increase in 4-hydroxyproline concentrations in control
mice but levels were comparable in WTD-fed GATA4iKO and
chow-fed controls (Fig. 3C). In agreement with these results, Sir-
ius Red staining revealed reduced collagen ﬁbers in GATA4iKO
mice compared with controls (Fig. 3D). Protein expression of
a-SMA was undetectable in liver homogenates of chow-fed
controls, whereas WTD feeding caused a pronounced increase
in a-SMA abundance in control but not GATA4iKO mice
(Fig. 3E). Immunostaining for a-SMA was performed as a marker
for myoﬁbroblast and HSC activation. Staining was restricted
around arterial walls and showed 16.3% positivity in WTD-fed
GATA4iKO mice compared to 70.4% positivity in WTD-fed control
mice (Fig. 3F middle and Supplementary Fig. 3). Thus, WTD led to
a mild but signiﬁcant hepatic ﬁbrosis only in control mice.
Hepatic transcript levels of collagen type I (73%), collagen type
III (42%), tissue inhibitor of metalloproteinases 1 (69%), and actin,
alpha-2 (53%) were downregulated in GATA4iKO compared with
control mice (Table 2). The mRNA expression of peroxisome pro-
liferator-activated receptor gamma (Pparg), a suppressor of HSC
activation, was 7.1-fold upregulated in GATA4iKO mice (Table 2).
Haematoxylin and eosin staining indicated lower immune cell
inﬁltration in WTD-fed GATA4iKO mice compared with controls
(Supplementary Fig. 4). We also observed fewer CD45-positive
cells in GATA4iKO mice (Supplementary Fig. 4). Transcript levels
of the inﬂammatory cytokines tumor necrosis factor alpha
(59%), interferon gamma (57%), interleukin 1b (40%), interleukin
6 (48%), and interleukin 12 (42%) were also downregulated in
WTD-fed GATA4iKO mice (Table 2).
GATA4iKO fails to protect mice against MCDD-induced hepatic
steatosis
We observed that the protective effects of GATA4iKO were absent
when mice were challenged with MCDD. MCDD feeding led to a
similar extent of weight loss (Supplementary Fig. 5) and hepatic
injury in both genotypes as indicated by comparable levels of
plasma AST, ALT, and LDH (Table 3). Hepatic accumulation of
TG and FFA was unaffected (Fig. 4A and B). Assessment of liver
damage as determined by haematoxylin and eosin as well as Sir-
ius Red staining also indicated signiﬁcant fat accumulation and
ﬁbrosis in both genotypes (Fig. 4C and D). In accordance, mRNA
expression of genes involved in lipogenesis and ﬁbrosis was
unchanged (Table 4).Discussion
In this report, we show that WTD but not MCDD-fed GATA4iKO
mice accumulate less hepatic TG and have reduced ﬁbrosis than
control mice. These ﬁndings suggest that intestinal deﬁciency
of GATA4 has a role on hepatic metabolism and preventsvol. 57 j 1061–1068
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Fig. 2. Glucagon-like peptide 1 (GLP-1)-AMP-activated protein kinase (AMPK) pathway is active in GATA4iKO mice. (A) Jejunal periodic acid Schiff (PAS) cells/nucleus
expressed in percent. Representative images of sections stained with PAS to reveal secretory cell types (pink) and nuclei (blue) in control and GATA4iKO jejunum. (B) Jejunal
GLP-1 positive cells/nucleus expressed in percent. Representative images of sections immunohistochemically stained for GLP-1 positive cells (black) and nuclei (blue) in
control and GATA4iKO jejunum. (C) Protein expression of AMPK, phosphorylated pAMPK(Y172), (D) acetyl-CoA carboxylase alpha (ACC) and pACC(S79, inhibitory phosphate)
in control and GATA4iKO livers. Numerical values below the blots represent mean relative densities. Values represent means ± SE. ⁄p <0.05, ⁄⁄p <0.01.
JOURNAL OF HEPATOLOGYdiet-induced liver damage only in a setting that mimics meta-
bolic disease. We had previously reported that GATA4iKO mice
were resistant to diet-induced obesity on long-termWTD feeding
[17]. A reduction in intestinal lipid absorption leads to a compen-
satory increase in hepatic DNL. Although GATA4iKO mice showed
reduced intestinal TG absorption, hepatic DNL was suppressed.
We speculate that GLP-1 leads to hepatic protection in GATA4iKO
mice since TG-induced GLP-1 release is increased [17]. Hepatic
protection by GLP-1 has also been demonstrated in genetic or
dietary models that resemble obesity and metabolic syndrome
but not under MCDD conditions. Therefore, GLP-1 release could
be one of the endocrine mechanisms involved in the observed
suppression of hepatic DNL in GATA4iKO mice. It has been
reported that exendin-4, a GLP-1 receptor agonist, signiﬁcantly
reduces hepatic steatosis in genetically obese ob/ob mice and
exerts a direct effect on the reduction of hepatic steatosis
[23,24]. We found more GLP-1 positive cells and increased GLP-
1 mRNA expression in GATA4iKO jejuna. These ﬁndings are in
good correlation with data obtained in rats that have undergone
IIS [14]. GLP-1 is known to suppress hepatic lipogenesis via acti-
vation of the AMPK pathway [21]. In livers from GATA4iKO mice,
increased intestinal GLP-1 secretion resulted in AMPK phosphor-
ylation, leading to phosphorylation and inhibition of its target
gene ACC, a key lipogenic enzyme. A recent study has shown that
AMPK activation phosphorylates SREBP-1c at Ser372 and thus
inhibits the cleavage and subsequent nuclear translocation of this
lipogenic transcription factor [25]. Our results indicateJournal of Hepatology 2012AMPK-mediated inhibition of SREBP-1c maturation and subse-
quent downregulation of DNL being operative in livers of
GATA4iKO mice. We conclude that apart from reduced intestinal
absorption [17], GLP-1-mediated suppression of hepatic DNL is
an important contributor to the observed hepatic protection in
GATA4iKO mice.
The major cellular event in the development of liver ﬁbrosis is
the triggering of quiescent HSC into an active state [26]. Pparg is a
known suppressor of HSC activation. Increased serum leptin lev-
els have a net pro-ﬁbrotic effect on the liver since leptin inhibits
Pparg gene expression in HSC [27]. In contrast, adiponectin inhib-
its HSC proliferation and suppresses DNL by inhibiting SREBP1c
maturation. Therefore, adiponectin attenuates progression of
both alcoholic and NAFLD [28,29]. We also found decreased tran-
script levels of ﬁbrotic and inﬂammatory marker genes and an
increase of Pparg mRNA in the liver of GATA4iKO mice, indicating
reduced HSC activation. GATA4iKO mice have decreased serum
leptin (even on normal chow) and increased adiponectin concen-
trations [17,30]. We speculate that the leptin and adiponectin
status in GATA4iKO mice leads to the observed upregulation in
Pparg transcript levels in a HSC and not hepatocyte-speciﬁc man-
ner. The effect of these adipokines on the activity and expression
of hepatocyte Pparg is so far unknown. Expression of a-SMA, a
marker of activated HSC, was reduced in GATA4iKO livers sup-
porting our hypothesis that a favorable adipokine status in
GATA4iKO mice may operate as an additional protective mecha-
nism against ﬁbrosis.vol. 57 j 1061–1068 1065
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Fig. 3. GATA4iKO mice have reduced hepatic lipid peroxidation and ﬁbrosis
upon 20 weeks of WTD feeding. (A) Hepatic thiobarbituric acid reactive species
levels determined as lM malondialdehyde adduct (MDA)/g liver tissue of control
and GATA4iKO mice (n = 5/group). (B) Phosphorylated (T180/Y182) and total levels
of the stress-induced p38 mitogen-activated protein kinase (p38) in livers from
control and GATA4iKO mice. Numerical values below blots represent mean
relative densities ± SE. (C) 4-Hydroxyproline concentrations converted into mg
collagen/g liver (for conversion formula refer to methods) in chow-fed control,
WTD-fed control and WTD-fed GATA4iKO mice (n = 4–5/group). (D) Representa-
tive images of liver sections stained for Sirius Red revealing collagen ﬁbers (red),
cytoplasm (yellow) and nuclei (gray). (E) Protein expression of alpha-smooth
muscle actin (a-SMA) in livers from chow and WTD-fed control and WTD-fed
GATA4iKO mice. Protein expression of calnexin was determined as loading
control. (F) Representative images of liver sections immunostained for a-SMA
(black) and nuclei (blue). Values are means ± SE. ⁄p <0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.001.
Table 3. Plasma parameters for hepatic damage in MCDD-fed GATA4iKO mice
compared to controls.
Control GATA4iKO
ALT (IU/L) 147.60 ± 32.37 84.20 ± 17.74
AST (IU/L) 104.20 ± 20.93 78.40 ± 27.84
LDH (IU/L) 269.40 ± 40.14 232.60 ± 35.25 
Values are means ± SE (n = 4/group).
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Fig. 4. Intestinal GATA4 deﬁciency does not protect from methionine and
choline-deﬁcient diet (MCDD)-induced hepatic steatosis. Control and
GATA4iKO mice (n = 4/group) were fed MCDD for 3 weeks. (A) Hepatic TG and
(B) FFA concentrations determined in hepatic lipid extracts. (C) Representative
images of liver sections stained for haematoxylin and eosin. (D) Representative
images of liver sections stained for Sirius Red revealing collagen ﬁbers (red),
cytoplasm (yellow) and nuclei (gray). Values represent means ± SE.
Research ArticleIn summary, our results provide evidence that GATA4iKO in
mice reduces intestinal TG uptake and lowers hepatic DNL
through increased GLP-1 production. Our ﬁndings imply beneﬁ-1066 Journal of Hepatology 2012cial effects of GATA4iKO protecting against NAFLD and hepatic
steatosis under conditions of metabolic syndrome.vol. 57 j 1061–1068
Table 4. mRNA fold change and p value for various genes in MCDD-fed
GATA4iKO mice compared to controls.
Gene name Fold 
change
p value
Lipogenesis
Sterol regulatory element-binding protein-1c 0.798 0.737
CD36 antigen 1.778 0.131
Glycerol-3-phosphate acyltransferase 1 1.074 0.905
Fatty acid synthase 2.060 0.089
Acetyl-CoA carboxylase alpha 1.639 0.156
Stearoyl-CoA desaturase 1 1.832 0.080
Fibrosis
Collagen type I 0.910 0.822
Collagen type III 1.158 0.675
Tissue inhibitor of metalloproteinases 1 1.027 0.968
Tissue inhibitor of metalloproteinases 2 1.378 0.49
Actin, alpha-2 0.998 1
Values are means ± SE (n = 4/group).
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